GNFTF - Genfit And PBC: Is Elafibranor A Contender?
Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela
Investment Thesis
Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high unmet medical needs. Elafibranor, the lead investigative drug candidate, is in Phase 3 clinical trial for NASH and in Phase 2 clinical trials for pediatric NASH as well as primary biliary cholangitis ((PBC)), the focus of this article.
Elafibranor is a new generation dual PPAR-α/d agonist that lack PPAR-γ responses and is